These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 34507318)

  • 1. Current Alzheimer disease research highlights: evidence for novel risk factors.
    Brenowitz WD; Xiang Y; McEvoy CT; Yang C; Yaffe K; Le WD; Leng Y
    Chin Med J (Engl); 2021 Sep; 134(18):2150-2159. PubMed ID: 34507318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Key Peptides and Proteins in Alzheimer's Disease.
    Penke B; Bogár F; Paragi G; Gera J; Fülöp L
    Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond the sleep-amyloid interactions in Alzheimer's disease pathogenesis.
    Ning S; Jorfi M
    J Neurophysiol; 2019 Jul; 122(1):1-4. PubMed ID: 30864847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
    Bloom GS
    JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.
    Frankfort SV; Tulner LR; van Campen JP; Verbeek MM; Jansen RW; Beijnen JH
    Curr Clin Pharmacol; 2008 May; 3(2):123-31. PubMed ID: 18700307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
    Koychev I; Hofer M; Friedman N
    J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prion-like Properties of Amyloid-beta Peptide and Tau: Is there Any Risk of Transmitting Alzheimer's Disease During Neurosurgical Interventions?
    Padilla-Zambrano HS; García-Ballestas E; Quiñones-Ossa GA; Sibaja-Perez AE; Agrawal A; Moscote-Salazar LR; Menéndez-González M
    Curr Alzheimer Res; 2020; 17(9):781-789. PubMed ID: 33280597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypothermia as a risk factor for Alzheimer disease.
    Almeida MC; Carrettiero DC
    Handb Clin Neurol; 2018; 157():727-735. PubMed ID: 30459036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease.
    Okonkwo OC; Alosco ML; Griffith HR; Mielke MM; Shaw LM; Trojanowski JQ; Tremont G;
    Arch Neurol; 2010 Jun; 67(6):688-96. PubMed ID: 20558388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
    Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
    Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. It's complicated: The relationship between sleep and Alzheimer's disease in humans.
    Lucey BP
    Neurobiol Dis; 2020 Oct; 144():105031. PubMed ID: 32738506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A critical analysis of the 'amyloid cascade hypothesis'.
    Armstrong RA
    Folia Neuropathol; 2014; 52(3):211-25. PubMed ID: 25310732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between amyloid-β and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease.
    Kristofikova Z; Ricny J; Kolarova M; Vyhnalek M; Hort J; Laczo J; Sirova J; Ripova D
    J Alzheimers Dis; 2014; 42 Suppl 3():S91-8. PubMed ID: 24670397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic noise exposure and Alzheimer disease: Is there an etiological association?
    Cui B; Li K
    Med Hypotheses; 2013 Oct; 81(4):623-6. PubMed ID: 23899629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy.
    McGeer PL; McGeer EG
    Acta Neuropathol; 2013 Oct; 126(4):479-97. PubMed ID: 24052108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Added value of cerebrospinal fluid multimarker analysis in diagnosis and progression of dementia.
    Álvarez I; Diez-Fairen M; Aguilar M; González JM; Ysamat M; Tartari JP; Carcel M; Alonso A; Brix B; Arendt P; Pastor P
    Eur J Neurol; 2021 Apr; 28(4):1142-1152. PubMed ID: 33236496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.